These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1558 related items for PubMed ID: 23628309

  • 1. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
    Lamm D, Brausi M, O'Donnell MA, Witjes JA.
    Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
    [Abstract] [Full Text] [Related]

  • 2. Salvage combination intravesical immunotherapy with Bacillus Calmette-Guérin and interferon-α2B: impact on recurrence, progression, and survival.
    Prasad SM, Eyre S, Loughlin KR.
    Hosp Pract (1995); 2013 Jan; 41(4):31-9. PubMed ID: 24145587
    [Abstract] [Full Text] [Related]

  • 3. Treatment of bacillus Calmette-Guerin refractory non-muscle invasive bladder cancer.
    Turker P, Turkeri L.
    Arch Esp Urol; 2013 Nov; 66(9):833-40. PubMed ID: 24231293
    [Abstract] [Full Text] [Related]

  • 4. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
    Shepherd AR, Shepherd E, Brook NR.
    Cochrane Database Syst Rev; 2017 Mar 08; 3(3):CD012112. PubMed ID: 28268259
    [Abstract] [Full Text] [Related]

  • 5. Intravesical bacillus Calmette-Guerin immunotherapy after previous prostate radiotherapy for high-grade non-muscle-invasive bladder cancer.
    Rao MV, Ellimoottil C, Sondej T, Flanigan RC, Quek ML.
    Urol Oncol; 2013 Aug 08; 31(6):857-61. PubMed ID: 21868262
    [Abstract] [Full Text] [Related]

  • 6. Treatment options available for bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer.
    Yates DR, Brausi MA, Catto JW, Dalbagni G, Rouprêt M, Shariat SF, Sylvester RJ, Witjes JA, Zlotta AR, Palou-Redorta J.
    Eur Urol; 2012 Dec 08; 62(6):1088-96. PubMed ID: 22959049
    [Abstract] [Full Text] [Related]

  • 7. Evaluating the cost-utility of intravesical Bacillus Calmette-Guérin versus radical cystectomy in patients with high-risk non-muscle-invasive bladder cancer in the UK.
    Grabe-Heyne K, Henne C, Odeyemi I, Pöhlmann J, Ahmed W, Pollock RF.
    J Med Econ; 2023 Dec 08; 26(1):411-421. PubMed ID: 36897006
    [Abstract] [Full Text] [Related]

  • 8. The role of bacillus Calmette-Guérin in the treatment of non-muscle-invasive bladder cancer.
    Gontero P, Bohle A, Malmstrom PU, O'Donnell MA, Oderda M, Sylvester R, Witjes F.
    Eur Urol; 2010 Mar 08; 57(3):410-29. PubMed ID: 19969411
    [Abstract] [Full Text] [Related]

  • 9. Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.
    Gandhi NM, Morales A, Lamm DL.
    BJU Int; 2013 Aug 08; 112(3):288-97. PubMed ID: 23517232
    [Abstract] [Full Text] [Related]

  • 10. Intravesical therapy for bladder cancer.
    Williams SK, Hoenig DM, Ghavamian R, Soloway M.
    Expert Opin Pharmacother; 2010 Apr 08; 11(6):947-58. PubMed ID: 20205607
    [Abstract] [Full Text] [Related]

  • 11. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
    Giannarini G, Birkhäuser FD, Recker F, Thalmann GN, Studer UE.
    Eur Urol; 2014 Apr 08; 65(4):825-31. PubMed ID: 24144432
    [Abstract] [Full Text] [Related]

  • 12. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
    Arends TJ, Nativ O, Maffezzini M, de Cobelli O, Canepa G, Verweij F, Moskovitz B, van der Heijden AG, Witjes JA.
    Eur Urol; 2016 Jun 08; 69(6):1046-52. PubMed ID: 26803476
    [Abstract] [Full Text] [Related]

  • 13. Developments in intravesical therapy for non-muscle-invasive bladder cancer.
    Lammers RJ, Witjes JA.
    Expert Rev Anticancer Ther; 2010 Dec 08; 10(12):1903-16. PubMed ID: 21110757
    [Abstract] [Full Text] [Related]

  • 14. Impact of previous bacille Calmette-Guérin failure pattern on subsequent response to bacille Calmette-Guérin plus interferon intravesical therapy.
    Gallagher BL, Joudi FN, Maymí JL, O'Donnell MA.
    Urology; 2008 Feb 08; 71(2):297-301. PubMed ID: 18308107
    [Abstract] [Full Text] [Related]

  • 15. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
    Järvinen R, Marttila T, Kaasinen E, Rintala E, Aaltomaa S, Kallio J, Liukkonen T, Puolakka VM, Seppänen M, Tuhkanen K, Vaarala M, Viitanen J, Boström PJ, FinnBladder Group.
    Eur Urol; 2015 Oct 08; 68(4):611-7. PubMed ID: 25748117
    [Abstract] [Full Text] [Related]

  • 16. Bacillus Calmette-Guérin treatment of non-muscle invasive bladder cancer.
    Sylvester RJ.
    Int J Urol; 2011 Feb 08; 18(2):113-20. PubMed ID: 21091799
    [Abstract] [Full Text] [Related]

  • 17. Is intravesical Bacillus Calmette-Guérin therapy superior to chemotherapy for intermediate-risk non-muscle-invasive bladder cancer? An ongoing debate.
    Han KS, You D, Jeong IG, Kwon T, Hong B, Hong JH, Ahn H, Ahn TY, Kim CS.
    J Korean Med Sci; 2015 Mar 08; 30(3):252-8. PubMed ID: 25729246
    [Abstract] [Full Text] [Related]

  • 18. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat EM, Hernández V, Kaasinen E, Palou J, Rouprêt M, van Rhijn BWG, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R.
    Eur Urol; 2017 Mar 08; 71(3):447-461. PubMed ID: 27324428
    [Abstract] [Full Text] [Related]

  • 19. Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancer.
    Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED.
    J Urol; 2007 May 08; 177(5):1727-31. PubMed ID: 17437798
    [Abstract] [Full Text] [Related]

  • 20. The efficacy of intravesical bacillus Calmette-Guerin in the treatment of patients with pT1 stage non-muscle-invasive bladder cancer.
    Ajili F, Darouiche A, Chebil M, Boubaker S.
    Ultrastruct Pathol; 2013 Aug 08; 37(4):278-83. PubMed ID: 23789613
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 78.